JP2023504195A5 - - Google Patents
Info
- Publication number
- JP2023504195A5 JP2023504195A5 JP2022534221A JP2022534221A JP2023504195A5 JP 2023504195 A5 JP2023504195 A5 JP 2023504195A5 JP 2022534221 A JP2022534221 A JP 2022534221A JP 2022534221 A JP2022534221 A JP 2022534221A JP 2023504195 A5 JP2023504195 A5 JP 2023504195A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- aso
- aspects
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025264280A JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945048P | 2019-12-06 | 2019-12-06 | |
| US62/945,048 | 2019-12-06 | ||
| US202062993971P | 2020-03-24 | 2020-03-24 | |
| US62/993,971 | 2020-03-24 | ||
| PCT/US2020/063157 WO2021113541A1 (en) | 2019-12-06 | 2020-12-03 | Antisense oligomers for treatment of conditions and diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Division JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023504195A JP2023504195A (ja) | 2023-02-01 |
| JP2023504195A5 true JP2023504195A5 (https=) | 2023-12-07 |
Family
ID=76222665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534221A Pending JP2023504195A (ja) | 2019-12-06 | 2020-12-03 | 状態および疾患の処置のためのアンチセンスオリゴマー |
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025264280A Pending JP2026048892A (ja) | 2019-12-06 | 2025-12-18 | 状態および疾患の処置のためのアンチセンスオリゴマー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230116704A1 (https=) |
| EP (1) | EP4069256A4 (https=) |
| JP (2) | JP2023504195A (https=) |
| KR (1) | KR20220113743A (https=) |
| CN (1) | CN115087452A (https=) |
| AU (1) | AU2020395835A1 (https=) |
| BR (1) | BR112022010882A2 (https=) |
| CA (1) | CA3159162A1 (https=) |
| IL (1) | IL293531A (https=) |
| MX (1) | MX2022006858A (https=) |
| WO (1) | WO2021113541A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| EP4110919A4 (en) * | 2020-02-28 | 2024-06-05 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| JP2024534157A (ja) * | 2021-08-27 | 2024-09-18 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｓｃｎ１ａ発現を調節するための化合物及び方法 |
| KR20250087733A (ko) * | 2022-07-29 | 2025-06-16 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 화합물 |
| AU2023321711A1 (en) * | 2022-08-11 | 2025-02-20 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN121194802A (zh) * | 2023-02-14 | 2025-12-23 | 斯托克制药公司 | 反义寡聚物调配物 |
| MX2025013084A (es) * | 2023-05-03 | 2026-02-03 | Stoke Therapeutics Inc | Compuestos y métodos para tratar sujetos humanos |
| WO2026036032A1 (en) * | 2024-08-09 | 2026-02-12 | Amylyx Pharmaceuticals, Inc. | Formulations containing antisense oligonucleotides targeting calpain-2 |
| WO2026052819A1 (en) * | 2024-09-06 | 2026-03-12 | Ospedale San Raffaele S.R.L. | Gene therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503756B1 (en) * | 2000-09-22 | 2003-01-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of syntaxin 4 interacting protein expression |
| CN109112126B (zh) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| WO2017106377A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| WO2019224864A1 (ja) * | 2018-05-21 | 2019-11-28 | 国立研究開発法人理化学研究所 | Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法 |
| AU2020227825B2 (en) * | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
-
2020
- 2020-12-03 BR BR112022010882A patent/BR112022010882A2/pt unknown
- 2020-12-03 EP EP20897381.8A patent/EP4069256A4/en active Pending
- 2020-12-03 WO PCT/US2020/063157 patent/WO2021113541A1/en not_active Ceased
- 2020-12-03 CA CA3159162A patent/CA3159162A1/en active Pending
- 2020-12-03 AU AU2020395835A patent/AU2020395835A1/en active Pending
- 2020-12-03 JP JP2022534221A patent/JP2023504195A/ja active Pending
- 2020-12-03 IL IL293531A patent/IL293531A/en unknown
- 2020-12-03 CN CN202080095947.9A patent/CN115087452A/zh active Pending
- 2020-12-03 MX MX2022006858A patent/MX2022006858A/es unknown
- 2020-12-03 KR KR1020227023111A patent/KR20220113743A/ko active Pending
-
2022
- 2022-06-03 US US17/832,182 patent/US20230116704A1/en active Pending
-
2025
- 2025-12-18 JP JP2025264280A patent/JP2026048892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504195A5 (https=) | ||
| US20240230644A1 (en) | Methods of treating transthyretin (ttr) mediated amyloidosis | |
| US6969383B2 (en) | Method for treating severe tinnitus | |
| Williams et al. | Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error | |
| US9402884B2 (en) | Methods of treating pulmonary sarcoidosis | |
| KR20180004158A (ko) | Tpp1 제제 및 cln2 질환의 치료 방법 | |
| JP2009523802A (ja) | Ｃｎｓ状態のための治療剤の安定製剤の中枢投与 | |
| Groothoff et al. | Irreversible encephalopathy after treatment with high-dose intravenous metronidazole | |
| Eseonu et al. | Comparative analysis of monotherapy versus duotherapy antiseizure drug management for postoperative seizure control in patients undergoing an awake craniotomy | |
| KR20120048706A (ko) | 뇌종양 치료 방법 | |
| KR20220075329A (ko) | 알콜성 간염의 치료 | |
| Baszyńska-Wilk et al. | Peripheral neuropathy as a complication of diabetic ketoacidosis in a child with newly diagnosed diabetes type 1: a case report | |
| Saltoğlu et al. | Rhinocerebral zygomycosis treated with liposomal amphotericin B and surgery: Chirurgisch und mit liposomalem Amphotericin B behandelte rhinozerebrale Zygomykosen | |
| JP2010535772A (ja) | 慢性的微小血管障害を治療するためのポリマー療法 | |
| WO2024155986A2 (en) | Unc13a antisense oligonucleotides | |
| JP3916563B2 (ja) | Ｐ物質の投与を含む治療方法 | |
| Maxa et al. | Continuous‐infusion flumazenil in the management of chlordiazepoxide toxicity | |
| US20200061103A1 (en) | Inhibition of neurological disease | |
| CN102625656A (zh) | 用静脉内布洛芬治疗危重症患者 | |
| Pfister et al. | Severe intraventricular haemorrhage shown by computed tomography as an unusual manifestation of Wernicke's encephalopathy | |
| US11590105B2 (en) | Intrathecal administration of levetiracetam | |
| WO2025184653A1 (en) | Micro-invasive neural system for delivering therapeutic agents for the treatment of neurological disorders | |
| Torres et al. | 4CPS-030 Selective decontamination of the gastrointestinal tract in preventing ventilator-associated pneumonia in an intensive care unit | |
| Kumaraguru et al. | Effectiveness of 3% saline versus mannitol in children with cerebral oedema of non traumatic etiology | |
| Yoshida et al. | Neuromyelitis Optica Complicated by Ornithine Transcarbamylase Deficiency Treated Safely with Pulse Steroid Therapy |